Masimo Corporation MASI recently announced the FDA clearance of its Masimo SET-powered MightySat Medical Pulse Oximeter, available Over-The-Counter (OTC) to consumers without a prescription.

Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her ...

Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

Masimo sells a range of devices used for patient monitoring that feature a proprietary pulse oximetry technology called Signal Extraction Technology (SET). In the latest update on that patent spat ...

Masimo Corp. and Apple Inc. have filed dueling post-trial briefs in a California federal court, following a retrial over ...

Our mission is to improve life, improve patient outcomes; and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusion ™ pulse oximetry, introduced in 1995, has been shown in ...

Offers optional dual IBP, and EtCo 2 — Now with Masimo SET ® Pulse Oximetry! The fully-functional Waveline Touch features a 12.1" color TFT display with a touch-screen interface. It features ...

Masimo traded as high as $178.84 and last traded at $178.84, with a volume of 28200 shares traded. The stock had previously closed at $174.65. Several other research firms have also commented on MASI.